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chemotherapeutic agents. Furthermore, in the original case
description [2], the disease relapsed, despite a 12-month
course of antimicrobials. It was not until after bilateral upper
lung lobectomies and additional chemotherapy that cure was
achieved.
We describe the ﬁrst case of peritoneal infection with
M. heckeshornense, in the setting of a patient with end-stage
renal disease on PD. The peritonitis resolved without the
use of speciﬁc antimicrobial medications, and this can proba-
bly be attributed to the source control involving peritoneal
catheter removal and ﬂuid drainage. Adequate source control
alone has been found to be sufﬁcient to clear M. heckeshorn-
ense infections in multiple reports, and our case of M. hecke-
shornense peritonitis is consistent with these ﬁndings.
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Abstract
In clinical studies on bacteraemia, the negativity of blood cul-
tures is an important endpoint for comparing the efﬁcacy of dif-
ferent therapeutic regimens. In FAN anaerobic blood culture
medium (BacT/ALERT system), daptomycin displayed increased
MIC against Staphylococcus aureus and improved abolishment of
its carryover effect in charcoal when compared with vancomy-
cin. Differences between these two drugs can lead to a false
interpretation of negative blood cultures. To compare different
antibiotic regimens for the treatment of bacteraemia, preliminary
studies are mandatory to ensure that ex vivo antibiotic behaviour
is similar in the blood-culture system used.
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Vancomycin remains the backbone of treatment for serious
infections caused by methicillin-resistant Staphylococcus aureus
(MRSA) strains, in particular for bacteraemia and endocardi-
tis [1,2]. However, emergence of S. aureus strains with inter-
mediate susceptibility [3] or that are even resistant to
vancomycin is worrying [4]. Furthermore, the pharmaco-
kinetic features of vancomycin, including low bactericidal
activity, weak post-antibiotic effect [5] and poor tissue distri-
bution [6], may explain its slow clinical response, notably
when the MIC is >1 mg/L [7].
Daptomycin, a cyclic lipopeptide that is active on Gram-
positive bacteria including MRSA [8], displays rapid concen-
tration-dependant bactericidal activity, which can reduce,
in vitro, the bacterial inoculum faster than vancomycin [5,9].
Daptomycin is approved for the treatment of complicated
skin and soft-tissue infections [10] and for the treatment of
bacteraemia and right-side endocarditis [11,12].
In clinical studies on bacteraemia, the negativity of blood
cultures is an important endpoint for comparing the efﬁcacy
of different therapeutic regimens [12,13]. However, bacterial
growth in blood cultures is affected by the presence of resid-
ual concentrations of antibiotics: the so-called ‘carryover
effect’. To resolve this issue, blood-culture medium contain-
ing resin or charcoal is often used to adsorb antibiotics
[14,15]. However, the inﬂuence of the medium on the ex vivo
efﬁcacy of different drugs, particularly for new antibiotics,
has not been fully studied. Herein, using the BacT/ALERT
system (BioMerieux, Lyon, France), we have studied the
inﬂuence of a blood-culture medium that contained charcoal
(FAN anaerobic BacT/ALERT FN) on the bacterial viability
of S. aureus in the presence of various concentrations of dap-
tomycin or vancomycin.
Taking into account that daptomycin binds to the cyto-
plasmic membrane via a Ca2+-dependant process, the MICs
of S. aureus ATCC29213 were assessed in Muller Hinton
(MH) broth medium with an inoculum of 104 CFU/mL sup-
plemented or not with 50 mg/L of Ca2+ [16,17]. Because the
FAN anaerobic medium is supplemented with Brain Heart
Infusion (BHI), the MICs were also performed in the BHI
broth. As previously described [5,17], in the absence of
Ca2+supplementation, daptomycin MICs were one to three
log2 dilutions higher: 2 mg/L vs. 1 mg/L in MH, and 16 mg/L
vs. 2 mg/L in BHI (Table 1). In the absence of Ca2+ supple-
mentation, the differences observed for MIC values obtained
in BHI and MH are explained by the composition of the
media, in particular the basic concentration of Ca2+ (3 mg/L
vs. 37 mg/L for BHI and MH, respectively). As expected, the
FAN anaerobic medium that contained charcoal led to a
signiﬁcant increase in the MICs, from 2 to 16 mg/L for
vancomycin and 16 to >256 mg/L for daptomycin, compared
with the medium without charcoal (Table 1). However,
adsorption by charcoal seemed to be more efﬁcient for dap-
tomycin than for vancomycin.
To reproduce in vitro the clinical conditions of blood cul-
ture collected from patients with staphylococcal bacteraemia
and treated with vancomycin or daptomycin, bacterial-
growth experiments were performed using an ex vivo blood
culture (EVBC). The EVBC mixture was prepared as follows:
horse blood, containing 10–60 mg/L of daptomycin or vanco-
mycin, corresponding to concentrations close to those
expected in human serum, was inoculated with 1, 10 and
100 CFU/mL, corresponding to the bacterial loads encoun-
TABLE 1. MICs of vancomycin and daptomycin for the Staphylococcus aureus ATCC29213 strain according to the medium
used
Medium used
Daptomycin MIC (mg/L) Vancomycin MIC (mg/L)
Without Ca2+
supplementation
Ca2+ supplementation
(50 mg/L)
Without Ca2+
supplementation
Ca2+ supplementation
(50 mg/L)
MH broth 2 1 1 1
BHI broth 16 2 2 2
Standard anaerobic BacT/ALERT SN (without charcoal) 16 ND 2 ND
FAN anaerobic BacT/ALERT FN (with charcoal) >256 ND 16 ND
ND, not done.
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tered during bacteraemia and endocarditis [18,19]. Aliquots
of 2, 5 or 10 mL of the EVBC mixture were then quickly
added to the bottle containing 40 mL of FAN anaerobic
medium, resulting in ﬁnal antibiotic concentrations of 0.5–
12 mg/L (Table 2). This ensured that the antibiotic did not
have sufﬁcient time to become active before introduction
into the bottle. The bottles were then incubated for 6 days
in a BacT/ALERT automate, and all experiments were per-
formed in duplicate. For daptomycin, after the addition of
10 mL of EVBC mixture, corresponding to the volume of
blood recommended by the manufacturer, EVBC became
positive for growth whatever the antibiotic concentration
and the bacterial inoculum tested (Table 2). In contrast, for
vancomycin, whatever the bacterial inoculum used, no
growth occurred when the ﬁnal antibiotic concentration in
the bottle was ‡5 mg/L, corresponding to vancomycin blood-
concentrations of ‡25 mg/L.
The discrepancy between the concentration of vancomy-
cin that inhibits growth in this experiment (5 mg/L) and the
MIC value found in the FAN anaerobic medium without
charcoal (16 mg/L) may be because of the difference in
the inoculum used in the two experiments (1–100 CFU/mL
in the bottle vs. 104 CFU/mL for MIC determinations). In
clinical practice, and according to the mode of administration
and the susceptibility of the S. aureus strain, the concentra-
tion of vancomycin in serum is usually between 15 (target
through concentrations for intermittent infusion) and 40 mg/
L (for continuous administration) [2,20]. In these conditions,
the inhibition of bacterial growth at a blood concentration of
25 mg/L, for a strain with a MIC of 1 mg/L in standard condi-
tions (Table 2), could overestimate the in vivo efﬁcacy of
vancomycin due to the carryover effect. This effect is ampli-
ﬁed when the bacterial load is very low (1 CFU/mL) because
inhibition of bacterial growth is even observed at a concen-
tration of 15 mg/L (Table 2). This effect became more pro-
nounced using the FAN aerobic BacT/ALERT FA medium
due to the volume of medium present in the bottle (30 mL
vs. 40 mL for FAN anaerobic), which led to an increased
antibiotic concentration in the FAN aerobic medium (data
not shown).
To overcome this issue, the volume of EVBC mixture
introduced into the bottle was reduced to decrease antibi-
otic concentration. For daptomycin, as expected from the
previous results, blood-volume reduction had no impact on
bacterial growth (Table 2). In contrast, for vancomycin the
cultures remained negative when an EVBC volume of 5 mL
was inoculated, corresponding to a ﬁnal concentration in the
bottle of ‡3 mg/L (vancomycin blood concentrations
‡30 mg/L). Finally, when an EVBC volume of 2 mL was
inoculated, all bottles became positive, even in the presence
of a blood concentration of 60 mg/L of vancomycin
(Table 2).
In conclusion, two important parameters were responsible
for the differences observed between vancomycin and
TABLE 2. Bacterial growth of the Staphylococcus aureus ATCC29213 strain in an ex vivo blood culture (EVBC)a
Volume (mL)
Antibiotic concentration
(mg/L) Inoculum (CFU/mL blood)
Ex vivo blood culturea Blood Bottle Vancomycin Daptomycin
1 10 100 1 10 100
10 10 2.0 + + + + + +
10 15 3.0 ) + + + + +
10 20 4.0 ) + + + + +
10 25 5.0 ) ) ) + + +
10 30 6.0 ) ) ) + + +
10 40 8.0 ) ) ) + + +
10 60 12.0 ) ) ) + + +
5 10 1.1 + + + + + +
5 15 1.7 + + + + + +
5 20 2.2 + + + + + +
5 25 2.8 ) + + + + +
5 30 3.3 ) ) ) + + +
5 40 4.4 ) ) ) + + +
5 60 6.7 ) ) ) + + +
2 10 0.5 + + + + + +
2 15 0.7 + + + + + +
2 20 1.0 + + + + + +
2 25 1.2 + + + + + +
2 30 1.4 + + + + + +
2 40 1.9 + + + + + +
2 60 2.8 + + + + + +
aEx vivo blood culture corresponded to a mixture of horse blood containing different concentrations of daptomycin or vancomycin, inoculated with three bacterial inocula
and introduced into FAN anaerobic medium with charcoal.
+, positive culture; ), negative culture.
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daptomycin in the positivity of the EVBC. First, although the
MICs of the two antibiotics were similar in standard condi-
tions, they were very different in BHI and FAN medium
without charcoal, which underlines the essential role of BHI.
Second, in the FAN medium with charcoal, daptomycin was
adsorbed more than vancomycin, which led to a stronger
reduction in the carryover effect. In this context, for studies
using negativity of blood cultures as the endpoint to com-
pare different antibiotic regimens, ex vivo differences in antibi-
otic behaviour introduce an important bias. Our results also
indicate that, for vancomycin, using the BacT/ALERT system,
10 mL of blood per bottle is probably not suitable for moni-
toring the negativity of blood culture. In this study, only
2 mL of blood allowed comparison between vancomycin and
daptomycin whatever the therapeutic antibiotic concentra-
tion. Investigators should be aware that, for studies that
compare different antibiotic regimens for the treatment of
bacteraemia, preliminary studies are mandatory to ensure
that ex vivo antibiotic behaviour is similar in the blood-culture
system used.
Acknowledgement
This work was supported by a Novartis grant.
Transparency Declaration
The authors have no conﬂicts of interest to declare.
References
1. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis:
diagnosis, antimicrobial therapy, and management of complications:
a statement for healthcare professionals from the Committee on
Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
Cardiovascular Disease in the Young, and the Councils on Clinical
Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia,
American Heart Association: endorsed by the Infectious Diseases
Society of America. Circulation 2005; 111: 394–434.
2. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophy-
laxis and treatment of methicillin-resistant Staphylococcus aureus
(MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589–
608.
3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC.
Methicillin-resistant Staphylococcus aureus clinical strain with reduced
vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135–
136.
4. Tenover FC, Weigel LM, Appelbaum PC et al. Vancomycin-resistant
Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob
Agents Chemother 2004; 48: 275–280.
5. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of
daptomycin and vancomycin on Enterococcus faecalis and Staphylococ-
cus aureus demonstrated by studies of initial killing and postantibiotic
effect and inﬂuence of Ca2+ and albumin on these drugs. Antimicrob
Agents Chemother 1991; 35: 1710–1716.
6. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR.
Vancomycin concentrations in infected and noninfected human bone.
Antimicrob Agents Chemother 1988; 32: 1320–1322.
7. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC
Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to
efﬁcacy of vancomycin for treatment of methicillin-resistant Staphylo-
coccus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–2402.
8. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipo-
peptide antibiotic for the treatment of serious Gram-positive infec-
tions. J Antimicrob Chemother 2005; 55: 283–288.
9. Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover
FC. In vitro activities of Daptomycin, Linezolid, and Quinupristin-
Dalfopristin against a challenge panel of Staphylococci and Entero-
cocci, including vancomycin-intermediate Staphylococcus aureus and
vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2003; 9:
389–393.
10. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomy-
cin 98-01 and 99-01 Investigators. The safety and efﬁcacy of dapto-
mycin for the treatment of complicated skin and skin-structure
infections. Clin Infect Dis 2004; 38: 1673–1681.
11. Bamberger DM. Bacteremia and endocarditis due to methicillin-resis-
tant Staphylococcus aureus: the potential role of daptomycin. Ther Clin
Risk Manag 2007; 3: 675–684.
12. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus
standard therapy for bacteremia and endocarditis caused by Staphylo-
coccus aureus. N Engl J Med 2006; 355: 653–665.
13. Chang FY, MacDonald BB, Peacock JE Jr et al. A prospective multi-
center study of Staphylococcus aureus bacteremia: incidence of endo-
carditis, risk factors for mortality, and clinical impact of methicillin
resistance. Medicine (Baltimore) 2003; 82: 322–332.
14. Spaargaren J, van Boven CP, Voorn GP. Effectiveness of resins in neu-
tralizing antibiotic activities in Bactec plus Aerobic/F culture medium.
J Clin Microbiol 1998; 36: 3731–3733.
15. Wilson ML, Weinstein MP, Mirrett S, Reimer LG, Feldman RJ, Chu-
ard CR. Controlled evaluation of Bact/Alert standard anaerobic and
FAN anaerobic blood culture bottles for the detection of bacteremia
and fungemia. J Clin Microbiol 1995; 33: 2265–2270.
16. European Committee for Antimicrobial Susceptibility Testing (EU-
CAST) of the European Society of Clinical Microbiology and Infec-
tious Diseases (ESCMID). Determination of minimum inhibitory
concentrations (MICs) of antibacterial agents by agar dilution. Clin
Microbiol Infect 2000; 6: 509–515.
17. Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests:
interpretive criteria, quality control, and effect of calcium on in vitro
tests. Diagn Microbiol Infect Dis 2000; 38: 51–58.
18. Schelonka RL, Chai MK, Yoder BA, Hensley D, Brockett RM, Ascher
DP. Volume of blood required to detect common neonatal patho-
gens. J Pediatr 1996; 129: 275–278.
19. Werner AS, Cobbs CG, Kaye DW. Studies on the bacteremia of bac-
terial endocarditis. JAMA 1967; 202: 199–203.
20. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for
the treatment of staphylococcal infections. Clin Microbiol Infect 2006;
12: 92–95.
CMI Research Notes 1267
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1262–1282
